Evidence map›Paper›PMID 42909551›Full record

ReviewMetabolic brain disease2026

Metabolic Dyshomeostasis, neuroinflammation, and glymphatic clearance deficits as convergent drivers of Alzheimer's disease: an exposome-based conceptual framework for prevention.

Ahmed M Abdelaziz, Reem M Eladawy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ahmed M AbdelazizDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish, 45511, Egypt. ahmed.abdelaziz@su.edu.eg.ORCID https://orcid.org/0000-0003-4747-8549
Reem M EladawyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish, 45511, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The repeated failures of anti-amyloid therapies in Alzheimer's disease (AD) have exposed critical limitations of the linear amyloid cascade hypothesis and underscored the need for a broader etiological framework. The objective of this review is to synthesise mechanistic evidence for an exposome‑based model of sporadic AD that integrates metabolic, inflammatory, and sleep/circadian contributions to brain aging. Epidemiological evidence indicates that up to 40% of AD risk is attributable to modifiable environmental and lifestyle factors. These factors, collectively termed the aging exposome, represent the cumulative measure of external exposures and the body's biological responses across the lifespan. The central hypothesis is that sporadic AD emerges from the synergistic convergence of three interconnected exposome domains, metabolic dyshomeostasis, chronic neuroinflammation, and sleep/circadian disruption, which collectively lower the threshold for clinical dementia through shared molecular hubs like NF‑κB, mTOR, and ER stress. Central to this model is brain insulin resistance, which impairs cerebral glucose utilization, compromises mitochondrial oxidative phosphorylation, and disrupts lipid homeostasis via ceramide/sphingomyelin imbalance, collectively driving bioenergetic failure, oxidative stress, and enhanced amyloid-β production. Concurrently, peripherally derived and central inflammatory signals prime microglia, upregulate β-secretase (BACE1), and activate complement-mediated synaptic pruning, while emerging evidence suggests that sleep fragmentation and circadian misalignment are hypothesized to reduce glymphatic clearance and sustain BACE1 elevation, although direct causal evidence in humans remains limited. These ostensibly disparate pathways are integrated by shared molecular hubs, NF-κB, mTOR, and endoplasmic reticulum stress, which establish a self-reinforcing vicious cycle that selectively damages the hippocampus and default mode network. This cumulative aging exposome burden exerts its greatest impact during the midlife metabolic storm window (ages 40-60) and exhibits sex-specific vulnerability. Collectively, metabolic, inflammatory, and sleep deficits amplify each other via shared hubs; midlife is a critical, sex‑specific vulnerability window; and multi‑domain prevention is rational, though causal proof requires exposome‑wide and pragmatic trials. This reframes sporadic AD as an exposome‑driven syndrome, favoring simultaneous metabolic, immune, and sleep interventions over single‑target approaches.

Indexed as

Alzheimer DiseaseExposomeGlymphatic SystemHomeostasisNeuroinflammatory DiseasesAgingAnimalsBrainHumansInflammationAging exposomeAlzheimer''s diseaseInsulin resistancemTORNeuroinflammationNF-κBPreventionSleep disruption

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.